An open-label, partially randomized, cross-over, monocentric phase I study evaluating the pharmacokinetic profile of RhuDex [AV-1142742] in order to determine optimum doses of meglumine and RhuDex.

Trial Profile

An open-label, partially randomized, cross-over, monocentric phase I study evaluating the pharmacokinetic profile of RhuDex [AV-1142742] in order to determine optimum doses of meglumine and RhuDex.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2008

At a glance

  • Drugs AV 1142742 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors MediGene Ltd
  • Most Recent Events

    • 28 Nov 2007 Status changed from recruiting to completed.
    • 02 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top